About half of people with schizophrenia will meet criteria for a substance use disorder at some point in their lives, and the combination is associated with worse outcomes on almost every measure: more relapses, more hospitalisations, more homelessness, more incarceration, lower medication adherence, and shorter life expectancy. For decades, mental health services and addiction services in most countries were entirely separate — different clinics, different funding streams, different cultures, often actively hostile to each other. People with both conditions fell into the gap. Integrated Dual Disorder Treatment (IDDT) is the evidence-based response to that gap.
Integrated Dual Disorder Treatment combines mental health and substance use treatment in a single team that addresses both conditions simultaneously, using a stage-wise, motivation-based approach.
Why parallel treatment fails
Before IDDT, the standard approach was sequential or parallel treatment. Sequential meant: get clean first, then we'll treat your psychosis. Parallel meant: see a psychiatrist on Monday, an addiction counsellor on Thursday, and good luck synthesising the two. Both approaches reliably failed:
- People with active psychosis usually cannot complete an addiction programme designed for higher-functioning patients
- Twelve-step programmes sometimes discouraged psychiatric medication
- Mental health services often refused to treat people who were using substances
- The two clinicians rarely coordinated
- Patients fell through cracks, were discharged for non-compliance, or simply gave up
The IDDT model
IDDT was developed primarily by Robert Drake, Kim Mueser, and colleagues at Dartmouth in the 1980s and 1990s. SAMHSA later adopted it as a national evidence-based practice and published an implementation toolkit. The core features:
- One team treats both conditions
- One treatment plan integrates psychiatric and substance use goals
- Stage-wise treatment matches the intervention to the person's readiness
- Motivational interviewing is woven throughout
- Long-term perspective — recovery is measured in years, not weeks
- Comprehensive services — housing, vocational support, family work, medication management
- Assertive outreach for people who don't engage easily
- Reduction of negative consequences (harm reduction) is acceptable as an interim goal
The stages of treatment
IDDT uses a stage model adapted from the addictions field:
- Engagement — building a working relationship; the goal is regular contact, not behaviour change yet.
- Persuasion — helping the person see that substance use is contributing to problems they want to solve. Heavy use of motivational interviewing.
- Active treatment — concrete work on reducing use: skills, support, sometimes medication for addiction.
- Relapse prevention — maintaining gains, addressing setbacks.
Importantly, the team does not push people to a stage they aren't ready for. The patient who has just started attending appointments doesn't need a relapse prevention plan; they need to keep coming. Attempting to skip stages is one of the predictable ways IDDT fails.
What the evidence shows
Multiple studies through the 1990s and 2000s, including the New Hampshire dual disorders study (Drake et al.), have shown IDDT to be superior to parallel treatment on outcomes including:
- Reductions in substance use over time
- Higher rates of stable housing
- Fewer hospitalisations and incarcerations
- Better quality of life
- Higher engagement and retention in treatment
The effects accumulate over years rather than months. Short-term studies often underestimate the model's value because the early stages (engagement, persuasion) are about laying foundations rather than producing rapid change.
Substances most commonly involved
Among people with schizophrenia, the most common substance use disorders are:
- Tobacco — roughly 60% smoke; see our smoking cessation guide
- Cannabis — see cannabis and psychosis
- Alcohol — see alcohol and schizophrenia
- Stimulants — particularly methamphetamine, with strong effects on psychosis
IDDT addresses all of these, often with explicit attention to the role each substance plays in the person's life (sleep, social connection, managing voices, anxiety relief).
How medications fit
Medication for addiction is sometimes useful in IDDT and is not contraindicated by an antipsychotic in most cases:
- Naltrexone for alcohol use disorder
- Acamprosate for alcohol use disorder
- Varenicline and bupropion for tobacco
- Nicotine replacement therapy at adequate doses
- Buprenorphine or methadone for opioid use disorder
Decisions about combinations are made by the prescriber and the team, with attention to interactions and side effects.
Where IDDT is delivered
In the US, IDDT is most often found within Assertive Community Treatment teams, community mental health centres, and dedicated co-occurring disorders programmes. SAMHSA's National Helpline (1-800-662-HELP) can help locate services. State mental health authority websites usually list designated co-occurring programmes.
What it asks of patients
IDDT does not ask patients to stop using substances as a condition of receiving care. It asks them to keep showing up. Over time, with consistent engagement, motivational work, and support, most people make real reductions — sometimes complete abstinence, sometimes partial, often non-linear. The model treats relapse as part of the process rather than a reason to discharge.
The honest summary
IDDT is one of the best-supported interventions in serious mental illness care, and one of the most under-implemented. Where it is available, it can change the trajectory of co-occurring disorders that have resisted decades of treatment. If you or your loved one has both schizophrenia and a substance use disorder, asking for an integrated team — even by name — is a reasonable place to start.
This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.